Manchester City set to sign Wolves' Rayan Ait-Nouri for around £50 million, as they seek to resolve their left-back issue.
DOJ mandates Keysight to divest Spirent units to preserve competition in critical testing markets.
Bristol Myers and BioNTech form $11.1B partnership to co-develop next-generation cancer drug BNT327, aiming to accelerate trials and expand indications.
Manchester City set to sign Wolves' Rayan Ait-Nouri for around £50 million, as they seek to resolve their left-back issue.
DOJ mandates Keysight to divest Spirent units to preserve competition in critical testing markets.
Bristol Myers and BioNTech form $11.1B partnership to co-develop next-generation cancer drug BNT327, aiming to accelerate trials and expand indications.